Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 16818638)

1.

Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.

Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN.

Cancer Res. 2006 Jul 1;66(13):6649-56.

2.

Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.

Miyaki A, Yang P, Tai HH, Subbaramaiah K, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2009 Sep;297(3):G559-66. doi: 10.1152/ajpgi.00133.2009. Epub 2009 Jul 16.

3.

HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.

Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C.

Carcinogenesis. 2009 Oct;30(10):1796-804. doi: 10.1093/carcin/bgp183. Epub 2009 Jul 28.

4.

β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.

Smartt HJ, Greenhough A, Ordóñez-Morán P, Talero E, Cherry CA, Wallam CA, Parry L, Al Kharusi M, Roberts HR, Mariadason JM, Clarke AR, Huelsken J, Williams AC, Paraskeva C.

Gut. 2012 Sep;61(9):1306-14. doi: 10.1136/gutjnl-2011-300817. Epub 2011 Nov 14.

PMID:
22082586
5.

15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.

Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP.

Cancer Res. 2006 Aug 1;66(15):7818-23.

6.

FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.

Mimori K, Ishii H, Nagahara H, Sudo T, Yamashita K, Inoue H, Barnard GF, Mori M.

Cancer Res. 2006 Mar 1;66(5):2683-90.

7.

Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.

Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH.

Cancer Res. 2007 Jun 15;67(12):5587-93.

9.

Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.

Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, DuBois RN.

Cancer Res. 2008 Nov 15;68(22):9331-7. doi: 10.1158/0008-5472.CAN-08-2893.

10.

Regulation of prostaglandin transporters in colorectal neoplasia.

Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN.

Cancer Prev Res (Phila). 2008 Jul;1(2):93-9. doi: 10.1158/1940-6207.CAPR-07-0009. Epub 2008 Mar 19.

11.

Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.

Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Mol Cancer Ther. 2009 Nov;8(11):3130-9. doi: 10.1158/1535-7163.MCT-09-0270. Epub 2009 Nov 3.

12.

Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.

Castro-Sánchez L, Agra N, Llorente Izquierdo C, Motiño O, Casado M, Boscá L, Martín-Sanz P.

Int J Biochem Cell Biol. 2013 Nov;45(11):2501-11. doi: 10.1016/j.biocel.2013.08.005. Epub 2013 Aug 15.

PMID:
23954207
13.

Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.

Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC, Paraskeva C.

Cancer Res. 2006 Mar 15;66(6):3106-13.

14.

Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.

Li M, Xie J, Cheng L, Chang B, Wang Y, Lan X, Zhang D, Yin Y, Cheng N.

Cancer Invest. 2008 Nov;26(9):905-12. doi: 10.1080/07357900802146154.

PMID:
19034772
15.

Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.

Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G361-8. Epub 2005 Sep 29.

16.

15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.

Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, DuBois RN.

J Biol Chem. 2005 Feb 4;280(5):3217-23. Epub 2004 Nov 12.

17.

Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.

Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM.

Mol Pharmacol. 2007 Jun;71(6):1715-20. Epub 2007 Apr 5.

18.

Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation.

Lee MY, Chou CY, Tang MJ, Shen MR.

Clin Cancer Res. 2008 Aug 1;14(15):4743-50. doi: 10.1158/1078-0432.CCR-08-0234.

19.

Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.

Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartsev S.

J Immunol. 2009 Jun 15;182(12):7548-57. doi: 10.4049/jimmunol.0802358.

20.

15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.

Chi X, Freeman BM, Tong M, Zhao Y, Tai HH.

Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.

PMID:
19501039
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk